Fenway Health | The Fenway Institute

Research site

(Unclaimed)

Location

1340 Boylston Street, Boston, Massachusetts, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Emtricitabine

MK-8527

Atazanavir

fluorouracil

PrEP

Ritonavir

Alimatravir

Tenofovir

MK-8527-007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 44 total trials

Status recently updated

A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018) (EXPrESSIVE-18)

The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.

Not yet enrolling

Enrolling

HIV

Drug: Alimatravir

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs (ASCEND)

The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and...

Enrolling

HIV

Substance Use Disorder (SUD)

Drug: APRETUDE (cabotegravir)

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of a...

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: PTM Oral LEN

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) (PURPOSE 3)

The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofov...

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: Lenacapavir Injection

Drug: Lenacapavir Tablet

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) (PURPOSE 365)

The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absor...

Active, not recruiting

HIV Pre-exposure Prophylaxis

Drug: Lenacapavir Tablet

Drug: Lenacapavir Injection